News | June 14, 2021
Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
With the acquisition of these further shares, TWPL has now become company's subsidiary.
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
The company recently incorporated a new entity in the name of Lupin Digital Health Limited
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
Subscribe To Our Newsletter & Stay Updated
